<DOC>
	<DOCNO>NCT00657150</DOCNO>
	<brief_summary>The primary objective trial demonstrate non-inferiority 220 mg oral dabigatran etexilate compare 40 mg subcutaneous enoxaparin administer daily . Safety efficacy compare treatment group .</brief_summary>
	<brief_title>Dabigatran Etexilate Compared With Enoxaparin Prevention Venous Thromboembolism ( VTE ) Following Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Patients schedule undergo primary , unilateral , elective total hip arthroplasty . Male female 18 year age old . Patients give write informed consent study participation . Exclusion criterion : Patients weigh less 40 kg . History bleed diathesis . Patients investigator judgement perceive excessive risk bleeding , example , constitutional acquire coagulation disorder anticipate need quinidine , verapamil restrict medication treatment period ( see Section 4.2.2 ) . Major surgery trauma ( e.g. , hip fracture ) within 3 month enrolment . Recent unstable cardiovascular disease ( investigators opinion ) uncontrolled hypertension , ongoing time enrolment history myocardial infarction within 3 month enrolment . Any history haemorrhagic stroke follow intracranial pathology : bleeding , neoplasm , Atriovenous ( AV ) malformation aneurysm . Ongoing treatment Venous Thromboembolism ( VTE ) . Clinically relevant bleeding ( gastrointestinal , pulmonary , intraocular urogenital bleeding ) within 6 month enrolment . Gastric duodenal ulcer within one year enrolment . Liver disease expect potential impact survival ( ie , hepatitis B C , cirrhosis ) . This include Gilberts syndrome hepatitis A complete recovery . Active liver disease liver disease decrease survival ( e.g , acute hepatitis , chronic active hepatitis , cirrhosis ) Alanine Aminotransferase ( ALT ) &gt; 3 x ULN . Known severe renal insufficiency ( CrCl &lt; 30 ml/min ) . Note : CrCl calculate serum creatinine elevate renal insufficiency suspect . See Appendix 10.1 calculation . Elevated creatinine , investigator opinion , contraindicate venography . Treatment anticoagulant , clopidogrel , ticlopidine , abciximab , aspirin &gt; 162.5 mg/day NSAID 1/2 &gt; 12 hour within 7 day prior hip replacement surgery OR anticipate need patient receive study medication prior 24 hour last administration blind study medication ( COX2 selective inhibitor allow ) . Anticipated required use intermittent pneumatic compression electric stimulation lower limb . Premenopausal woman ( last menstruation within 1 year prior sign informed consent ) : Are pregnant . Are nurse . Are childbearing potential NOT practice acceptable method birth control , NOT plan continue practice acceptable method throughout study . Acceptable method birth control include intrauterine device ; oral , implantable injectable contraceptive surgical sterility . Known allergy radio opaque contrast medium . History thrombocytopenia , include heparininduced thrombocytopenia , platelet count &lt; 100,000 cells/microliter randomisation . Allergy heparins dabigatran etexilate . Active malignant disease current cytostatic treatment . Patients disease free least 5 year . Participation clinical trial within 30 day randomisation . Leg amputee . Known alcohol drug abuse would interfere completion study . Contraindications enoxaparin . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>